
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Perspective on Treating Advanced Marginal Zone Lymphoma
A 65-Year-Old Man With Advanced Nodal MZL
November 2014
History & Physical:
Treatment History:
November 2015
November 2017
June 2018

